IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9221903 B1

PDFFull Text
Date of Patent:
Dec. 29, 2015

Filed:

Nov. 26, 2013

Method of inhibiting binding or activity of mif by administering a mif antagonist

Applicants:

Baxter International Inc., Deerfield, IL (US);

Baxter Healthcare SA, Glattpark (Opfikon), CH;

Inventors:

Richard J. Bucala, Cos Cob, CT (US);

Lin Leng, New York, NY (US);

Christine N. Metz, Great Neck, NY (US);

Assignees:

Baxalta Incorporated, Bannockburn, IL (US);

Baxalta GmbH, Glattpark (Opfikon), CH;

Attorney:

Morgan, Lewis & Bockius LLP

Primary Examiner:

Bridget E Bunner

Int. Cl.
CPC ...
A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 35/00 (2006.01); C07K 16/24 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); C07K 16/28 (2006.01); C07K 16/40 (2006.01); C12N 9/90 (2006.01); C12N 15/113 (2010.01); C07K 14/47 (2006.01); C07K 14/52 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/24 (2013.01); A61K 38/17 (2013.01); C07K 16/2833 (2013.01); C07K 16/40 (2013.01); C12N 9/90 (2013.01); C12N 15/1138 (2013.01); G01N 33/5047 (2013.01); G01N 33/6863 (2013.01); A61K 38/1709 (2013.01); A61K 38/19 (2013.01); A61K 2039/505 (2013.01); C07K 14/47 (2013.01); C07K 14/52 (2013.01); C12Y 503/02001 (2013.01); C12Y 503/03012 (2013.01); G01N 2333/52 (2013.01); G01N 2333/99 (2013.01); G01N 2500/02 (2013.01);
Abstract

Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.

Find Patent Forward Citations

Loading…